Does a statistically significant survival benefit of erlotinib plus gemcitabine for advanced pancreatic cancer translate into clinical significance and value? - Reply

被引：1
|
作者：
Moore, Malcolm J. [1 ]
Au, Heather Jane
Parulekar, Wendy
机构：
[1] Univ Toronto, Princess Margaret Hosp, NCI,Div Med Oncol & Hematol, Canada Clin Trials Grp Gastrointestinal Dis Commi, Toronto, ON, Canada
[2] Queens Univ, NCI, Canada Clin Trials Grp, Kingston, ON, Canada
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2007年 / 25卷 / 28期
关键词：
D O I：
10.1200/JCO.2007.13.1862
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：4508 / 4508
页数：1
相关论文
共 50 条
  • [31] Clinical Significance of Increased Skeletal Muscle Mass During Nab-Paclitaxel Plus Gemcitabine Treatment in Patients With Advanced Pancreatic Cancer
    Iede, Kiyotsugu
    Yamada, Terumasa
    Ishida, Tomo
    Tsuda, Yujiro
    Nakashima, Shinsuke
    Tanida, Tsukasa
    Matsuyama, Jin
    Nakata, Ken
    Tominaga, Shusei
    PANCREAS, 2024, 53 (01) : e22 - e26
  • [32] Gemcitabine (G) fixed-lose-rate infusion (FDR) plus erlotinib (E) in patients with advanced pancreatic cancer (APC)
    Munoz Llarena, A.
    Mane, J.
    Lopez-Vivanco, G.
    Ruiz de Lobera, A.
    Sancho, A.
    Iruarrizaga, E.
    Arruti, M.
    Marrodan, I.
    Fuente, N.
    Ballesteros, D.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (04)
  • [33] Phase II Trial of Erlotinib Plus Gemcitabine Chemotherapy in Korean Patients with Advanced Pancreatic Cancer and Prognostic Factors for Chemotherapeutic Response
    Park, Semi
    Chung, Moon Jae
    Park, Jeong Youp
    Chung, Jae Bock
    Bang, Seungmin
    Park, Seung Woo
    Song, Si Young
    GUT AND LIVER, 2013, 7 (05) : 611 - 615
  • [34] Phase II trial of Erlotinib plus Gemcitabine chemotherapy in Korean patients with advanced pancreatic cancer and prognostic factors of chemotherapeutic response
    Park, Semi
    Bang, Seungmin
    Park, Seung Woo
    Chung, Jae Bock
    Song, Si Young
    CANCER RESEARCH, 2009, 69
  • [35] Efficacy of Prophylactic Minocycline Treatment for Skin Toxicities Induced by Erlotinib Plus Gemcitabine in Patients with Advanced Pancreatic Cancer: A Retrospective Study
    Akira Shinohara
    Masafumi Ikeda
    Hiroyuki Okuyama
    Misaki Kobayashi
    Hideki Funazaki
    Shuichi Mitsunaga
    Satoshi Shimizu
    Izumi Ohno
    Hideaki Takahashi
    Yasuhiko Ichida
    Kunio Takahashi
    Takuji Okusaka
    Shinichiro Saitoh
    American Journal of Clinical Dermatology, 2015, 16 : 221 - 229
  • [36] Efficacy of Prophylactic Minocycline Treatment for Skin Toxicities Induced by Erlotinib Plus Gemcitabine in Patients with Advanced Pancreatic Cancer: A Retrospective Study
    Shinohara, Akira
    Ikeda, Masafumi
    Okuyama, Hiroyuki
    Kobayashi, Misaki
    Funazaki, Hideki
    Mitsunaga, Shuichi
    Shimizu, Satoshi
    Ohno, Izumi
    Takahashi, Hideaki
    Ichida, Yasuhiko
    Takahashi, Kunio
    Okusaka, Takuji
    Saitoh, Shinichiro
    AMERICAN JOURNAL OF CLINICAL DERMATOLOGY, 2015, 16 (03) : 221 - 229
  • [37] A randomized phase II clinical trial of gemcitabine, oxaliplatin, erlotinib combination chemotherapy versus gemcitabine and erlotinib in previously untreated patients with locally advanced or metastatic pancreatic cancer.
    Lim, Sung Hee
    Yun, Jina
    Lee, Min-Young
    Kim, Han Jo
    Kim, Kyoung Ha
    Kim, Se Hyung
    Lee, Sang-Cheol
    Bae, Sang Byung
    Kim, Chan Kyu
    Lee, Namsu
    Lee, Kyu Taek
    Park, Sung Kyu
    Hong, Dae Sik
    Choi, Hyun Jong
    Moon, Jong Ho
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (04)
  • [38] Randomized, cross-over phase III study of gemcitabine plus erlotinib followed by capecitabine versus capecitabine plus erlotinib followed by gemcitabine in advanced pancreatic cancer - a multicenter trial of the "Arbeitsgemeinschaft Internistische Onkologie" (AIO)
    Boeck, S.
    Vehling-Kaiser, U.
    Waldschmidt, D.
    Kettner, E.
    Maerten, A.
    Winkelmann, C.
    Klein, S.
    Kojouharoff, G.
    Jung, A.
    Heinemann, V
    ONKOLOGIE, 2010, 33 : 25 - 25
  • [39] Gemcitabine plus erlotinib followed by capecitabine versus capecitabine plus erlotinib followed by gemcitabine in advanced pancreatic cancer: final results of a randomised phase 3 trial of the 'Arbeitsgemeinschaft Internistische Onkologie' (AIO-PK0104)
    Heinemann, Volker
    Vehling-Kaiser, Ursula
    Waldschmidt, Dirk
    Kettner, Erika
    Maerten, Angela
    Winkelmann, Cornelia
    Klein, Stefan
    Kojouharoff, Georgi
    Gauler, Thomas C.
    von Weikersthal, Ludwig Fischer
    Clemens, Michael R.
    Geissler, Michael
    Greten, Tim F.
    Hegewisch-Becker, Susanna
    Rubanov, Oleg
    Baake, Gerold
    Hoehler, Thomas
    Ko, Yon D.
    Jung, Andreas
    Neugebauer, Sascha
    Boeck, Stefan
    GUT, 2013, 62 (05) : 751 - 759
  • [40] Clinical benefit with gemcitabine (GEM) as first-line therapy for patients with advanced pancreatic cancer (APC)
    Manzano, H
    Esquerdo, G
    Rifa, J
    Aguiar, D
    Arrivi, A
    Pazo, R
    Martin, J
    Terrasa, J
    ANNALS OF ONCOLOGY, 1998, 9 : 54 - 54
12345